CN116113411A - 用于治疗软组织肉瘤的联用药物 - Google Patents
用于治疗软组织肉瘤的联用药物 Download PDFInfo
- Publication number
- CN116113411A CN116113411A CN202180057118.6A CN202180057118A CN116113411A CN 116113411 A CN116113411 A CN 116113411A CN 202180057118 A CN202180057118 A CN 202180057118A CN 116113411 A CN116113411 A CN 116113411A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- luoti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
属于生物医药领域，涉及用于治疗软组织肉瘤的联用药物，其包括抗PD‑L1抗体和安罗替尼或其药学上可接受的盐。另外，还提供了含抗PD‑L1抗体和安罗替尼或其药学上可接受的盐的药物组合或药物组合物在制备用于治疗软组织肉瘤的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (35)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010814874 | 2020-08-13 | ||
| CN2020108148746 | 2020-08-13 | ||
| PCT/CN2021/112549 WO2022033585A1 (zh) | 2020-08-13 | 2021-08-13 | 用于治疗软组织肉瘤的联用药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116113411A true CN116113411A (zh) | 2023-05-12 |
Family
ID=80247701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180057118.6A Pending CN116113411A (zh) | 2020-08-13 | 2021-08-13 | 用于治疗软组织肉瘤的联用药物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230285554A1 (zh) |
| EP (1) | EP4197554A1 (zh) |
| CN (1) | CN116113411A (zh) |
| WO (1) | WO2022033585A1 (zh) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964108B (zh) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术（太仓）有限公司 | 抗pd-l1抗体 |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| JP2022526694A (ja) * | 2019-01-25 | 2022-05-26 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍治療用の併用医薬組成物 |
| CN113939315B (zh) * | 2019-05-30 | 2024-04-02 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗黑色素瘤的联用药物组合物 |
| CN113905761A (zh) * | 2019-06-10 | 2022-01-07 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗驱动基因阳性肺癌的联用药物组合物 |
| CN112168961A (zh) * | 2019-07-03 | 2021-01-05 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
-
2021
- 2021-08-13 WO PCT/CN2021/112549 patent/WO2022033585A1/zh unknown
- 2021-08-13 US US18/019,612 patent/US20230285554A1/en active Pending
- 2021-08-13 CN CN202180057118.6A patent/CN116113411A/zh active Pending
- 2021-08-13 EP EP21855635.5A patent/EP4197554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230285554A1 (en) | 2023-09-14 |
| EP4197554A1 (en) | 2023-06-21 |
| WO2022033585A1 (zh) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113347996B (zh) | 治疗肿瘤的联用药物组合物 | |
| WO2020187152A1 (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| CN112168961A (zh) | 治疗结直肠癌的联用药物组合物 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| CN113939315B (zh) | 治疗黑色素瘤的联用药物组合物 | |
| CN113018429A (zh) | 治疗卵巢癌的药物组合 | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| CN112121048A (zh) | 用于联合治疗食管癌的喹啉类化合物 | |
| WO2021219138A1 (zh) | 用于治疗肾癌的联用药物 | |
| WO2022002153A1 (zh) | 用于治疗肿瘤的药物 | |
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| CN116036265A (zh) | 用于癌症的联用药物 | |
| CN117642181A (zh) | 用于治疗食管癌的药物组合 | |
| CN116173198A (zh) | 用于肝癌术后辅助治疗的联用药物 | |
| CN118201963A (zh) | 用于治疗非小细胞肺癌的药物组合 | |
| CN117597146A (zh) | 用于治疗胃癌和/或食管胃结合部癌的联用药物 | |
| CN116209443A (zh) | 治疗小细胞肺癌的药物组合 | |
| CN116370641A (zh) | 用于治疗消化系统恶性肿瘤的联用药物 | |
| CN116510005A (zh) | 治疗肿瘤的联用药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |